Why the study?
Testing for lupus anticoagulant autoantibodies in patients using rivaroxaban may lead to false positives.
Rivaroxaban use can cause false-positive lupus anticoagulant autoantibody test results, which may confound hereditary thrombophilia screening in patients with pulmonary embolism.
Pulmonary embolism refers to obstructions of the pulmonary arterial bed due to various etiologies.In most cases, pulmonary embolisms are caused by blood clots that travel to the lungs from the deep veins in the legs or, more rarely, from veins in other parts of the body.Today, the new generation oral anticoagulants are preferred for the treatment of pulmonary embolism due to their ease of use and greater reliability.The new oral anticoagulants are novel direct-acting medications that are selective for a specific coagulation factor, either thrombin or activated factor Xa, among which Rivaroxaban has been used in many countries.Lupus anticoagulant autoantibodies are considered a common culprit in the etiology of pulmonary embolisms with no underlying risk factor, which may lead to false positives in patients using Rivaroxaban.A case with lupus anticoagulant autoantibody positivity due to rivaroxaban usage is presented here to draw attention to this issue.
No takes yet. Share an insight, caveat, or question.
Başaranoğlu et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: